Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1266014.RAo4wWw46IFlNKCgwTB_IfDrzEONFuGyMdhUAMlgIDlhM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1266014.RAo4wWw46IFlNKCgwTB_IfDrzEONFuGyMdhUAMlgIDlhM130_assertion type Assertion NP1266014.RAo4wWw46IFlNKCgwTB_IfDrzEONFuGyMdhUAMlgIDlhM130_head.
- NP1266014.RAo4wWw46IFlNKCgwTB_IfDrzEONFuGyMdhUAMlgIDlhM130_assertion description "[However, many patients with HNSCC respond poorly to the EGFR inhibitors (EGFRI) cetuximab and erlotinib, despite tumor expression of EGFR.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266014.RAo4wWw46IFlNKCgwTB_IfDrzEONFuGyMdhUAMlgIDlhM130_provenance.
- NP1266014.RAo4wWw46IFlNKCgwTB_IfDrzEONFuGyMdhUAMlgIDlhM130_assertion evidence source_evidence_literature NP1266014.RAo4wWw46IFlNKCgwTB_IfDrzEONFuGyMdhUAMlgIDlhM130_provenance.
- NP1266014.RAo4wWw46IFlNKCgwTB_IfDrzEONFuGyMdhUAMlgIDlhM130_assertion SIO_000772 25712126 NP1266014.RAo4wWw46IFlNKCgwTB_IfDrzEONFuGyMdhUAMlgIDlhM130_provenance.
- NP1266014.RAo4wWw46IFlNKCgwTB_IfDrzEONFuGyMdhUAMlgIDlhM130_assertion wasDerivedFrom befree-2016 NP1266014.RAo4wWw46IFlNKCgwTB_IfDrzEONFuGyMdhUAMlgIDlhM130_provenance.
- NP1266014.RAo4wWw46IFlNKCgwTB_IfDrzEONFuGyMdhUAMlgIDlhM130_assertion wasGeneratedBy ECO_0000203 NP1266014.RAo4wWw46IFlNKCgwTB_IfDrzEONFuGyMdhUAMlgIDlhM130_provenance.